dsdsa

product

Hot sale Lidocaine Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

Our products and solutions are greatly recognized and trustworthy by customers and may fulfill constantly changing financial and social requires for Mesylate-Azd9291, Octreotide, 107007-99-8, Living by quality, development by credit is our eternal pursuit, We firmly believe that after your visit we will become long-term partners.
Hot sale Lidocaine Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai Detail:

Product name Tofacitinib Citrate
Synonyms (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate; CP 690500-10; CP 690550-10; (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate
CAS No. 540737-29-9
Appearance Off white to white powder
Molecular Formula C16H20N6O.C6H8O7
Molecular Weight 504.50
Application Pharmaceutical grade or research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Tofacitinib Citrate (CAS #540737-29-9)

ITEMS

STANDARDS

RESULTS

Appearance

Off white to white powder

Off white powder

Identification

HPLC; IR; HNMR

Complies

Solubility

Soluble in DMSO at 100mg/ml, very poorly soluble in ethanol, sparingly soluble in water etc.

Complies

Loss on Drying

≤0.5%

0.12%

Residue on ignition

≤0.1%

0.05%

Heavy metals

≤10ppm

Complies

Related Substances

Diastereomer (RS+SR) ≤0.1%

Single Impurity ≤0.15%

Total impurities ≤1.0%

0.05%

0.14%

0.18%

Enantiomorphism Isomers

≤0.2%

Complies

Residual Solvents

Ethanol ≤5000ppm

Methanol ≤3000ppm

Toluene ≤890ppm

Complies

Citrate Content

36.2%~40%

37.8%

Purity

≥99.0%

99.38%

Assay

60.68%~63.16% of Tofacitinib INN

98%~102% of Tofacitinib Citrate INN

62.04%

 

99.12%

Conclusion:Complies

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

Hot sale Lidocaine Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

Hot sale Lidocaine Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures

Hot sale Lidocaine Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai detail pictures


Related Product Guide:

We offer great strength in quality and development,merchandising,sales and marketing and operation for Hot sale Lidocaine Hydrochloride - High Purity 540737-29-9 Tofacitinib citrate for JAK Pathway Inhibitor – Yibai , The product will supply to all over the world, such as: Portland, America, Ghana, Insisting on the high quality generation line management and customers expert assistance, we now have designed our resolution to offer our buyers using the to start with amount getting and just after services practical experience. Maintaining the prevailing friendly relations with our buyers, we however innovate our solution lists all of the time to satisfy the brand new demands and adhere to the most up-to-date development of the market in Malta. We are ready to face the worries and make the improve to understand all the possibilities in international trade.
  • We are long-term partners, there is no disappointment every time, we hope to maintain this friendship later!
    5 Stars By Mario from Algeria - 2018.06.09 12:42
    Reasonable price, good attitude of consultation, finally we achieve a win-win situation,a happy cooperation!
    5 Stars By Sara from Tunisia - 2018.11.02 11:11
    Write your message here and send it to us